The Germany-headquartered contract research organization (CRO) received the payment for transitioning a program into pre-clinical development for the treatment of endometriosis.
The multi-target endometriosis alliance with Bayer was established in October 2012 with the goal of developing three clinical candidates for the treatment of endometriosis.
An Evotec spokesperson told Outsourcing-Pharma.com the five-year alliance “is well on track and very successful.”
Both companies contribute drug targets and technology infrastructures, sharing responsibility for early research and pre-clinical characterization of potential clinical candidates.
“This pre-clinical milestone is again an important step on the way to the achievement of this goal,” the spokesperson explained.